Your browser doesn't support javascript.
loading
Valor pronóstico del nuevo sistema de etapificación internacional en mieloma múltiple: Comparación con el sistema de Durie-Salmon / Prognostic value of the new international staging system in multiple myeloma: Comparison with Durie-Salmon staging system
Conté L., Guillermo; Figueroa M., Gastón; Lois V., Vivianne; Cabrera C., María Elena; León R., Alvaro; García L., Hernán; Rojas R., Hernán.
Afiliación
  • Conté L., Guillermo; Universidad de Chile. Hospital Clínico. Sección de Hematología. CL
  • Figueroa M., Gastón; Universidad de Chile. Hospital Clínico. Sección de Hematología. CL
  • Lois V., Vivianne; Hospital Barros Luco T. Santiago. CL
  • Cabrera C., María Elena; Hospital Salvador. Santiago. CL
  • León R., Alvaro; Universidad Austral de Chile. Hospital Regional de Valdivia. CL
  • García L., Hernán; Hospital San Borja A. Santiago. CL
  • Rojas R., Hernán; Hospital Sótero del Río. Santiago. CL
Rev. méd. Chile ; 136(1): 7-12, ene. 2008. ilus, tab
Article en Es | LILACS | ID: lil-483214
Biblioteca responsable: BR1.1
ABSTRACT

Background:

Since 1975, the Durie-Salmon staging system (D&S) has been a widely accepted prognostic classification of multiple myeloma (MM) patients. Recently, the new International Staging System (ISS) was developed using only the values of albumin and betaZ-microglobulin.

Aim:

To compare survival of patients with MM treated in six medical centers in Chile according to the D&S system and the new ISS. Material and

methods:

Retrospective analysis of demographic information, clinical features and survival rate of patients treated between 1998 and 2002, and grouped according to both systems.

Results:

Information of 81 patients aged 38 to 90 years (43 women) was retrieved. According D&S system 11 percent were in stage I 12 percent in stage II and 73 percent in stage III According to ISS, 34 percent were in stage I 35 percent in stage II and 31 percent in stage III Median of survival of all patients was 32 months. Both staging systems had a prognostic value. However, median survival for the three stages of the ISS system was significantly different (67, 29 and 14 months in stages III and III, respectively, p =0.02). Patients in advanced stages II and III of the ISS, had a higher frequency of anemia, hypercalcemia, renal failure and hypoalbuminemia. In stages II and III of ISS the presence of renal failure was associated with a non significantly different lower survival.

Conclusions:

The ISS is a simple and effective grouping method for patients with MM, that predicts survival. The presence of renal insufficiency might identify a subgroup of patients included in stages II and III of ISS with a higher mortality.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 01-internacional Base de datos: LILACS Asunto principal: Mieloma Múltiple / Estadificación de Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male País/Región como asunto: America do sul / Chile Idioma: Es Revista: Rev. méd. Chile Asunto de la revista: MEDICINA Año: 2008 Tipo del documento: Article País de afiliación: Chile Pais de publicación: Chile
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 01-internacional Base de datos: LILACS Asunto principal: Mieloma Múltiple / Estadificación de Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male País/Región como asunto: America do sul / Chile Idioma: Es Revista: Rev. méd. Chile Asunto de la revista: MEDICINA Año: 2008 Tipo del documento: Article País de afiliación: Chile Pais de publicación: Chile